Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 2 KEYSTEP-004 study.

被引：0

作者：

Rimassa, Lorenza

Li, Daneng

Ikeda, Masafumi

Yarchoan, Mark

Ryoo, Baek-Yeol

Kossler, Thibaud

Lim, Ho-Yeong

Kwiatkowski, Mariusz

Chang, Ting-Tsung

Kim, Jee Hyun

Casadei-Gardini, Andrea

Kudo, Masatoshi

Ren, Zhenggang

Calvo, Maria Varela

Llovet, Josep M.

Zhang, Yayan

Hatogai, Ken

Siegel, Abby B.

Cheng, Ann-Lii

机构：

[1] Humanitas Univ, IRCCS Humanitas Res Hosp Rozzano, Pieve Emanuele & Humanitas Canc Ctr, Dept Med Sci, Milan, Italy

[2] City Hope Natl Comprehens Canc Ctr, Duarte, CA USA

[3] Natl Canc Ctr Hosp East, Kashiwa, Japan

[4] Johns Hopkins Univ, Baltimore, MD USA

[5] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[6] Geneva Univ Hosp, Geneva, Switzerland

[7] Samsung Med Ctr, Seoul, South Korea

[8] Szpital Wojewodzki Mikolaja Kopernika Koszalinie, Oddzial Dzienny Chemioterapii, Koszalin, Poland

[9] Natl Cheng Kung Univ Hosp, Tainan, Taiwan

[10] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea

[11] San Raffaele Res Hosp, Milan, Italy

[12] Kindai Univ, Fac Med, Osaka, Japan

[13] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China

[14] Hosp Univ Cent Asturias, Oviedo, Spain

[15] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Liver Dis, New York, NY USA

[16] Merck & Co Inc, Rahway, NJ USA

[17] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

[18] Natl Taiwan Univ Hosp, Taipei, Taiwan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

283-424-425; 613-135-244-3829-325; 261-492-2769; 298-145-222-184-1022-9124; 613-3267-3650-6749; 613-615-646-2548-6283; 613-615-646-3281; 261-492-199-2823; 6; 5; 3; 2; 242; 28; 4; 1;

D O I：

10.1200/JCO.2024.42.3_suppl.484

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：484 / 484

页数：1

共 50 条

[31] First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study.
D'Angelo, Sandra P.
Russell, Jeffrey
Hassel, Jessica Cecile
Lebbe, Celeste
Chmielowski, Bartosz
Rabinowits, Guilherme
Terheyden, Patrick
Brownell, Isaac
Zwiener, Isabella
Bajars, Marcis
Hennessy, Meliessa
Kaufman, Howard
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[32] First-line (1L) maintenance therapy with niraparib (nira) plus pembrolizumab (pembro) vs placebo plus pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase 3 ZEAL-1L study
Nagrial, Adnan
Ramalingam, Suresh S.
de Castro, Gilberto, Jr.
Garassino, Marina Chiara
Mazieres, Julien
Sanborn, Rachel
Smit, Egbert
Spigel, David R.
Thomas, Michael
Velcheti, Vamsidhar
Shi, Lei
Neibauer, Melissa Whipple
Stojadinovic, Alexander
Peters, Solange
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 204 - 205
[33] First-line (1L) maintenance therapy with niraparib (nira) plus pembrolizumab (pembro) vs placebo plus pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase III ZEAL-1L study
Ramalingam, S. S.
de Castro, G., Jr.
Garassino, M. C. C.
Mazieres, J.
Sanborn, R. E.
Smit, E. F. F.
Spigel, D. R.
Thomas, M.
Velcheti, V.
Zhi, E.
Whipple Neibauer, M.
Stojadinovic, A.
Peters, S.
ANNALS OF ONCOLOGY, 2021, 32 : S1030 - S1032
[34] A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459.
Sangro, Bruno
Park, Joong-Won
Dela Cruz, Christine Marie
Anderson, Jeffrey
Lang, Lixin
Neely, Jaclyn
Shaw, James W.
Cheng, Ann-Lii
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[35] CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Yau, T.
Park, J. W.
Finn, R. S.
Cheng, A-L.
Mathurin, P.
Edeline, J.
Kudo, M.
Han, K-H.
Harding, J. J.
Merle, P.
Rosmorduc, O.
Wyrwicz, L.
Schott, E.
Choo, S. P.
Kelley, R. K.
Begic, D.
Chen, G.
Neely, J.
Anderson, J.
Sangro, B.
ANNALS OF ONCOLOGY, 2019, 30 : 874 - +
[36] Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
Finn, Richard S.
Ryoo, Baek-Yeol
Merle, Philippe
Kudo, Masatoshi
Bouattour, Mohamed
Lim, Ho-Yeong
Breder, Valeriy Vladimirovich
Edeline, Julien
Chao, Yee
Ogasawara, Sadahisa
Yau, Thomas
Garrido, Marcelo
Chan, Stephen Lam
Knox, Jennifer J.
Daniele, Bruno
Ebbinghaus, Scot
Chen, Erluo
Siegel, Abby B.
Zhu, Andrew X.
Cheng, Ann-Lii
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[37] Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361.
Morales-Barrera, Rafael
Powles, Thomas
Ozguroglu, Mustafa
Csoszi, Tibor
Loriot, Yohann
Flechon, Aude
Matsubara, Nobuaki
Rodriguez-Vida, Alejo
Geczi, Lajos
Cheng, Susanna Y.
Fradet, Yves
Oudard, Stephane
Gunduz, Seyda
Ma, Junshui
Rajasagi, Mohini
Vajdi, Amir
Cristescu, Razvan
Imai, Kentaro
Moreno, Blanca Homet
Alva, Ajjai Shivaram
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[38] Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: Preliminary results from a phase 1b/2 study.
Lee, Keun-Seok
Wang, Xiaojia
Im, Young Hyuck
Zeng, Xiaohua
Li, Huiping
Wang, Kun
Li, Huiyan
Zhou, Ping
Bao, Yuanyuan
Jiang, Zefei
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[39] Subgroup analyses of a phase 1/2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC)
Ikeda, Masafumi
Ikeda, Kenji
Kudo, Masatoshi
Osaki, Yukio
Okusaka, Takuji
Tamai, Toshiyuki
Suzuki, Takuya
Hisai, Takashi
Miyagishi, Hideaki
Okita, Kiwamu
Kumada, Hiromitsu
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[40] Donafenib combined with anti-PD-1 antibody and transarterial chemoembolization (TACE) as first-line (1L) treatment for unresectable/advanced hepatocellular carcinoma (HCC)
Zhou, Jian
Yan, Zhiping
Wang, Zheng
Qiu, Shuang-Jian
Yang, Minjie
Zhu, Kai
Yi, Yong
Yu, Lei
Sun, Yun-Fan
Zhang, Bo
Yu, Jiaze
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →